Detalhe da pesquisa
1.
Genetic and phenotypic attributes of splenic marginal zone lymphoma.
Blood;
139(5): 732-747, 2022 02 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34653238
2.
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling.
Br J Haematol;
203(3): 416-425, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37580908
3.
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.
Blood;
137(22): 3027-3036, 2021 06 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33739404
4.
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Haematologica;
108(8): 2091-2100, 2023 08 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36632738
5.
Effects of the BTN162b2 mRNA COVID-19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia.
Hematol Oncol;
41(1): 120-127, 2023 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36156278
6.
Do GWAS-Identified Risk Variants for Chronic Lymphocytic Leukemia Influence Overall Patient Survival and Disease Progression?
Int J Mol Sci;
24(9)2023 Apr 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37175717
7.
The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches.
Int J Mol Sci;
23(9)2022 May 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35563634
8.
Cytomegalovirus reactivation after hematopoietic stem cell transplant with CMV-IG prophylaxis: A monocentric retrospective analysis.
J Med Virol;
93(11): 6292-6300, 2021 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33580523
9.
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group.
Hematol Oncol;
39(3): 326-335, 2021 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33739461
10.
Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.
Int J Mol Sci;
22(17)2021 Aug 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34502069
11.
Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies.
Int J Mol Sci;
22(4)2021 Feb 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33672997
12.
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Haematologica;
105(7): 1937-1947, 2020 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31582542
13.
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.
Haematologica;
105(2): 448-456, 2020.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31371416
14.
Investigating the association between physicians self-efficacy regarding communication skills and risk of "burnout".
Health Qual Life Outcomes;
18(1): 271, 2020 Aug 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32762755
15.
NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?
Int J Mol Sci;
21(23)2020 Nov 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33255988
16.
Acute Myeloid Leukemia in Patients Living with HIV Infection: Several Questions, Fewer Answers.
Int J Mol Sci;
21(3)2020 Feb 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32041199
17.
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.
Oncologist;
24(9): 1246-1252, 2019 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30940746
18.
BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors.
Blood;
129(5): 582-586, 2017 02 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27927646
19.
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study).
Oncologist;
23(9): 1033-1038, 2018 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29674440
20.
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.
Blood;
127(23): 2833-40, 2016 06 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27091875